Other languages Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Real-time Estimate Cboe BZX Other stock markets 01:32:04 2024-05-08 pm EDT			5-day change	1st Jan Change
42.2 ^USD	-3.88%		-8.22%	-29.39%

05:01pm	UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating	MT
01:51pm	Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises	May. 07
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	Apr. 26
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	Apr. 26
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	Apr. 09
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	Mar. 21
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	Mar. 20
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing	Mar. 14
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing	Mar. 11
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024	Mar. 11
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing	Mar. 05
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	Mar. 04
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	Feb. 27
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 26
Apellis Pharmaceuticals Receives Negative EU Committee Opinion for Pegcetacoplan	Jan. 26
Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application	Jan. 26
Apellis Pharmaceuticals Insider Sold Shares Worth $272,975, According to a Recent SEC Filing	Jan. 24
Apellis Pharmaceuticals Insider Sold Shares Worth $469,905, According to a Recent SEC Filing	Jan. 24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Other languages

Filters